aTyr Pharma Inc (LIFE)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:aTyr Pharma Inc (LIFE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011839
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
aTyr Pharma Inc (aTyr Pharma) is a biotherapeutics company that discovers and develops physiocrine-based therapies. The company’s resolaris is a potential intravenous protein therapeutic for the treatment of rare myopathies with an immune component. It offers phyisiocrine, which is a class of endogenous human proteins from amino acyl tRNA synthetases that function as extracellular signaling molecules in different physiologic settings. aTyr Pharma develops drugs for cancer, neurodegenerative diseases, inflammation, and metabolic disorders. The company collaborates with research institutions for its research and development activities. It has presence in the US and Hong Kong. aTyr Pharma is headquartered in San Diego, California, the US.

aTyr Pharma Inc (LIFE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
aTyr Pharma Raises USD76 Million in Series E Financing 11
aTyr Pharma Raises US$49 Million In Series D Financing 13
Partnerships 14
Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15
Equity Offering 16
aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 16
aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 17
aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 19
aTyr Pharma Raises USD86.3 Million in IPO of Shares 20
aTyr Pharma Inc – Key Competitors 22
aTyr Pharma Inc – Key Employees 23
aTyr Pharma Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 14, 2017: aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update 25
Aug 14, 2017: aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline 27
May 11, 2017: aTyr Pharma Announces First Quarter 2017 Operating Results 29
Mar 16, 2017: aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results 31
Nov 14, 2016: aTyr Pharma Announces Third Quarter 2016 Operating Results 33
Aug 10, 2016: aTyr Pharma Announces Second Quarter 2016 Operating Results 35
May 11, 2016: aTyr Pharma Announces First Quarter 2016 Operating Results 37
Mar 30, 2016: aTyr Pharma Announces Fourth Quarter 2015 Operating Results 38
Corporate Communications 39
Nov 01, 2017: aTyr Pharma Announces Leadership Transition 39
Apr 10, 2017: aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors 40
Apr 03, 2017: aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors 41
Mar 30, 2016: aTyr Pharma Appoints Sanjay Shukla, MD, MS, as Chief Medical Officer 42
Jan 06, 2016: aTyr Pharma Appoints Sanuj Ravindran, M.D., as Chief Business Officer 43
Product News 44
05/15/2017: aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar 44
Other Significant Developments 45
Jan 11, 2016: aTyr Provides Corporate Update And Outlook For 2016 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
aTyr Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
aTyr Pharma Raises USD76 Million in Series E Financing 11
aTyr Pharma Raises US$49 Million In Series D Financing 13
Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15
aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 16
aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 17
aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 19
aTyr Pharma Raises USD86.3 Million in IPO of Shares 20
aTyr Pharma Inc, Key Competitors 22
aTyr Pharma Inc, Key Employees 23
aTyr Pharma Inc, Subsidiaries 24

★海外企業調査レポート[aTyr Pharma Inc (LIFE)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HDR Inc:企業の戦略的SWOT分析
    HDR Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Exandal Corp:企業の戦略・SWOT・財務分析
    Exandal Corp - Strategy, SWOT and Corporate Finance Report Summary Exandal Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Cranswick plc:企業の戦略・SWOT・財務情報
    Cranswick plc - Strategy, SWOT and Corporate Finance Report Summary Cranswick plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Diagnostics For All Inc:企業の製品パイプライン分析2018
    Summary Diagnostics For All Inc (DFA) is a drug development company that develops and commercializes of new technology and practical diagnostic devices for diagnostic companies. The company uses patterned paper technology to create electrochemical clinical chemistry assays, immunoassays, assays, and …
  • Varian Medical Systems, Inc.:企業のM&A・事業提携・投資動向
    Varian Medical Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Varian Medical Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Yum China Holdings Inc (YUMC):企業の財務・戦略的SWOT分析
    Yum China Holdings Inc (YUMC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Jones Lang LaSalle Inc (JLL):企業の財務・戦略的SWOT分析
    Jones Lang LaSalle Inc (JLL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Kemin Industries Inc:企業の戦略・SWOT・財務情報
    Kemin Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Kemin Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Wockhardt Ltd (WOCKPHARMA):製薬・医療:M&Aディール及び事業提携情報
    Summary Wockhardt Ltd (Wockhardt) is a pharmaceutical company that manufactures and markets vaccines, active pharmaceutical ingredients, pharmaceutical and recombinant bio-pharmaceutical formulations. The company's product portfolio caters to various therapeutic areas including orthopedics, dental c …
  • Public Joint-Stock Company Commercial Bank Privatbank
    Public Joint-Stock Company Commercial Bank Privatbank - Strategy, SWOT and Corporate Finance Report Summary Public Joint-Stock Company Commercial Bank Privatbank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • ARMO Biosciences Inc:企業のM&A・事業提携・投資動向
    ARMO Biosciences Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ARMO Biosciences Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Wentworth Resources Ltd (WRL)-石油・ガス分野:企業M&A・提携分析
    Summary Wentworth Resources Limited (Wentworth) is an independent upstream oil and gas company. It conducts the exploration and development of oil and natural gas reserves. The company has producing gas assets in Tanzania, oil and gas exploration activities in both Mozambique and Tanzania. The compa …
  • China Gezhouba Group Company Limited (600068):企業の財務・戦略的SWOT分析
    China Gezhouba Group Company Limited (600068) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Blue Dolphin Energy Co (BDCO):企業の財務・戦略的SWOT分析
    Summary Blue Dolphin Energy Co (Blue Dolphin) operates as an oil and gas company that refines and markets petroleum products. The company own and operate pipeline assets and have leasehold interests in oil and gas properties. It also acquires, develops and explores oil and gas properties. Blue Dolph …
  • Jadason Enterprises Limited (J03):企業の財務・戦略的SWOT分析
    Jadason Enterprises Limited (J03) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Papeles y Cartones de Europa SA:企業の戦略・SWOT・財務情報
    Papeles y Cartones de Europa SA - Strategy, SWOT and Corporate Finance Report Summary Papeles y Cartones de Europa SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Petrolympic Ltd (PCQ):石油・ガス:M&Aディール及び事業提携情報
    Summary Petrolympic Ltd (Petrolympic) is an oil and gas exploration and development company that acquires, explores and develops light crude oil and natural gas in North America. The company holds interests in conventional natural gas and light oil projects in Gaspe Peninsula of Quebec. It holds int …
  • Prescient Therapeutics Ltd (PTX):企業の財務・戦略的SWOT分析
    Summary Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a clinical stage oncology company that develops novel drugs for the treatment of solid and hematological cancers. The company’s lead drug candidate includes PTX-200, a potent small molecule inhibitor of the …
  • Profectus BioSciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Profectus BioSciences Inc (Profectus), formerly Maryland Biotherapeutics Inc is a clinical-stage vaccine development company that designs and develops vaccines for infectious diseases and oncolytic vaccines for cancer immunotherapy. The company's products comprise genevax therapeutic vaccine …
  • Terumo BCT Inc:企業の戦略的SWOT分析
    Terumo BCT Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆